A real‐world data of Immune checkpoint inhibitors in solid tumors from India-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A real‐world data of Immune checkpoint inhibitors in solid tumors from India

Published:2021-02-16 Issue:5 Volume:10 Page:1525-1534
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Noronha Vanita¹,Abraham George¹^ORCID,Patil Vijay¹,Joshi Amit¹,Menon Nandini¹^ORCID,Mahajan Abhishek²,Janu Amit²,Jain Srushti¹,Talreja Vikas T¹,Kapoor Akhil¹,Kumar Singh Gunjesh¹,Khaddar Satvik¹,Gupta Kushal¹,Rathinasamy Narmadha¹,Srinivas Sujay¹,Agrawal Amit¹,Ventrapati Pradeep¹,Prabhash Kumar¹

Affiliation:

1. Department of Medical Oncology Tata Memorial Hospital Mumbai India

2. Department of Radiodiagnosis Tata Memorial Hospital Mumbai India

Funder

Amgen

Fresenius Biotech

Roche

Sanofi K.K.

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3617

Reference27 articles.

1. An Update on Immunotherapy for Solid Tumors: A Review

2. Immune Checkpoint Blockade: The New Frontier in Cancer Treatment

3. Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application

4. Role of immune-checkpoint inhibitors in lung cancer

5. Immune checkpoint inhibitors in renal cell carcinoma

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population;Future Oncology;2024-06-23

2. Precision Medicine and Clinical Trials in Advanced and Metastatic Oral Cancer;Journal of Maxillofacial and Oral Surgery;2024-06-17

3. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study;Targeted Oncology;2024-05

4. Addressing the affordability gap of novel cancer treatments in developing countries;PLOS Digital Health;2024-05-01

5. A Multicenter Study on the Challenges and Real-World Utilization of Immune Checkpoint Inhibitors in Resource-Constrained Settings: Insights and Implications from India;South Asian Journal of Cancer;2024-04-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3